WEBMar 29, 2021 · 1365TiP A phase I/II, open-label study of BBT-176, a triple mutation targeting EGFR TKI, in patients with NSCLC who progressed after prior EGFR TKI therapy - Annals of Oncology. Abstract | Volume 32, SUPPLEMENT 5, S1035, September 2021.